Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Cardiothoracic and Vascular Anesthesia

• Publication date

  1999-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1053-0770(99)90208-2PMID 10468249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Review of its Pharmacology and Therapeutic Efficacy in Reducing Blood Loss Associated with Cardiac Surgery

  2012cited by this paper
• Heparin coating with aprotinin reduces blood activation during coronary artery operations.

  1997cited by this paper
• Platelet deposition and fibrinogen binding on surfaces coated with heparin or friction-reducing polymers.

  1996cited by this paper
• Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model.

  1996cited by this paper
• Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting.

  1996cited by this paper
• Combined use of aprotinin and a heparin-bonded cardiopulmonary bypass system for aortic aneurysm repair.

  1995cited by this paper
• Hemostatic complications of cardiopulmonary bypass

  1995cited by this paper
• The blood saving potential of vortex versus roller pump with and without aprotinin

  1995cited by this paper
• Heparin-coated cBypass circuits

  1994cited by this paper
• Aprotinin effect on platelet function and clotting during cardiopulmonary bypass.

  1994cited by this paper
• Heparin-coated cardiopulmonary bypass circuits.

  1994cited by this paper
• Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.

  1993cited by this paper
• Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation.

  1993cited by this paper
• Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom.

  1993cited by this paper
• Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study.

  1993cited by this paper
• Aprotinin reduces cardiopulmonary bypass‐induced blood loss and inhibits fibrinolysis without influencing platelets

  1993cited by this paper
• Original articlePlatelet protection by aprotinin in cardiopulmonary bypass: Electron microscopic study

  1992cited by this paper
• Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study.

  1992cited by this paper
• High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients.

  1992cited by this paper
• Aprotinin Prevents Cardiopulmonary Bypass‐Induced Platelet Dysfunction: A Scanning Electron Microscope Study

  1992cited by this paper
• Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose.

  1992cited by this paper
• Proteins at Interfaces: Principles, Multivariate Aspects, Protein Resistant Surfaces, and Direct Imaging and Manipulation of Adsorbed Proteins

  1992cited by this paper
• Blood conservation techniques and platelet function in cardiac surgery.

  1991cited by this paper
• Platelet activation and aggregation during cardiopulmonary bypass.

  1991cited by this paper
• Temperature dependence of plasmin-induced activation or inhibition of human platelets.

  1991cited by this paper
• Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation.

  1991cited by this paper
• Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.

  1991cited by this paper
• Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.

  1991cited by this paper
• Platelet preservation during cardiopulmonary bypass with iloprost and Duraflo-II heparin-coated surfaces.

  1991cited by this paper
• Analysis of proteins adsorbed to glass from human plasma using immunoblotting methods.

  1990cited by this paper
• Bleeding complications associated with cardiopulmonary bypass.

  1990cited by this paper
• Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.

  1990cited by this paper
• Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass.

  1989cited by this paper
• Platelet preservation during cardiopulmonary bypass with aprotinin.

  1989cited by this paper
• The life of an artificial device in contact with blood: initial events and their effect on its final state.

  1988cited by this paper
• Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.

  1988cited by this paper
• Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit.

  1987cited by this paper
• Bleeding after cardiopulmonary bypass.

  1986cited by this paper
• PLATELETS ADHERE WHERE FLOW HAS LEFT FIBRINOGEN ON GLASS

  1983cited by this paper
• Application of a mechanical heart and lung apparatus to cardiac surgery.

  1954cited by this paper

• Platelet-sparing properties of aprotinin

  2024cites this paper
• Heparin coatings for improving blood compatibility of medical devices☆

  2017cites this paper
• Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea? Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass?

  2009cites this paper
• Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass?

  2009cites this paper
• Vergleichende Untersuchungen konventioneller und minimierter extrakorporaler Zirkulation bei aorto-koronaren Bypassoperationen

  2007cites this paper
• Aprotinin and hemostasis monitoring concerns during cardiac surgery.

  2004cites this paper
• Cardiopulmonary Bypass-Associated Coagulopathies and Prophylactic Therapy

  2004cites this paper
• Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors.

  2003cites this paper
• Use of Heparin-bonded Circuits in Cardiopulmonary Bypass Improves Clinical Outcome

  2002cites this paper
• Case 7--2001. Management during cardiopulmonary bypass of patients with presumed fish allergy.

  2001cites this paper
• Myocardial injury in cardiac surgery: the role of transfusion.

  2000cites this paper
• Aprotinin has direct platelet protective properties: fact or fiction?

  1999cites this paper
• Prevention of Ischemic Injury in Cardiac Surgery

  year unknowncites this paper